SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Esophageal cancer. Available from URL: http://www.cancer.org/downloads/PRO/EsophagealCancer.pdf [accessed April 21, 2004].
  • 2
    American Cancer Society. Estimated new cancer cases and deaths, by sex, US 2003. Available from URL: http://www.cancer.org/downloads/STT/CAFF2003PWsecured.pdf [accessed April 21, 2004].
  • 3
    Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000; 18: 455462.
  • 4
    Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1997; 335: 462467.
  • 5
    Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med. 1997; 337: 161167.
  • 6
    Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with local-regional esophageal carcinoma. J Clin Oncol. 2001; 15: 305313.
  • 7
    Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999; 17: 32703275.
  • 8
    Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002; 94: 641656.
  • 9
    Komaki R, Janjan NA, Ajani JA, et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Huntingt). 2000; 14(Suppl. 14): 3437.
  • 10
    Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003; 21: 29262933.
  • 11
    Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001; 92: 279286.
  • 12
    Schnirer II, Komaki R, Yao JC, et al. A pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001; 24: 9195.
  • 13
    Siwert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998; 85: 14571459.
  • 14
    Gibson MK, Forastiere AA. Combined-modality therapy for esophageal cancer: are we making progress? Cancer J. 2003; 9: 238239.
  • 15
    Kelsen DP, Ginsberg R, Pajak T, et al. Preoperative chemotherapy followed by operation versus operation alone for patients with localized esophageal cancers: a US national intergroup study. N Engl J Med. 1998; 339: 19791984.
  • 16
    Swisher S, Ajani J, Komaki R, et al. A CPT-11-Taxotere-5-FU regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with resectable esophageal or gastroesophageal carcinoma. Proc Am Soc Clin Oncol. 2003; 22: 272.
  • 17
    Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003; 21: 428432.
  • 18
    Swisher SG, Erasmus J, Maish M, et al. PET predicts pathologic response and long-term survival following preoperative chemoradiotherapy in esophageal cancer. ASCO virtual meeting. 2004 Gastrointestinal cancers symposium. Available from URL: http://www.asco.org/ac/1,1003_12-002511-00_18-0027-00_19-00253,00.asp [accessed April 21, 2004].